HIV-1 Immunogen: an overview of almost 30 years of clinical testing of a candidate therapeutic vaccine

References

• World Health Organization. HIV/AIDS fact sheet no. 360; 2015 [cited 2015 Oct 13]. Available from: http://www.who.int/mediacentre/factsheets/fs360/en/]
   Google Scholar
• U.S. Department of Health & Human Services. The global HIV/AIDS epidemic; global statistics; 2014 [cited 2015 Oct 13]. Available from: http://www.aids.gov/hiv-aids-basics/hiv-aids-101/global-statistics/
   Google Scholar
• World Health Organization. 10 Facts on HIV/AIDS; 2015 [cited 2015 Oct 13]. Available from: http://www.who.int/features/factfiles/hiv/facts/en/index5.html
   Google Scholar
• Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382:1525–1533.
   PubMed Web of Science ®Google Scholar
• Vella S, Schwartlander B, Sow SP, et al. The history of antiretroviral therapy and of its implementation in resource-limited areas of the world. AIDS. 2012;26:1231–1241.
   PubMed Web of Science ®Google Scholar
• Deeks SG, Autran B, Berkhout B, et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol. 2012;12:607–614.
   PubMed Web of Science ®Google Scholar
• The International AIDS Society Scientific Working Group on HIV Cure. Towards an HIV cure; full recommendations. 1st ed; 2012 [cited 2015 Oct 13]. Available from: http://www.iasociety.org/Web/WebContent/File/HIV_Cure_Full_recommendations_July_2012.pdf
   Google Scholar
• Vanham G, Van GE. Can immunotherapy be useful as a “functional cure” for infection with human immunodeficiency virus-1? Retrovirology. 2012;9:72.
   PubMed Web of Science ®Google Scholar
• Joos B, Fischer M, Kuster H, et al. HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A. 2008;105:16725–16730.
   PubMed Web of Science ®Google Scholar
• Adis International Ltd. HIV vaccine–immune response. AG 1661. IR-8101, IR8101, Remune, RG 83894. Drugs R D. 2002;3:411–420.
   PubMedGoogle Scholar
• Salk J. Prospects for the control of AIDS by immunizing seropositive individuals. Nature. 1987;327:473–476.
   PubMed Web of Science ®Google Scholar
• PR Newswire. The Immune Response Corporation granted patent in South Africa for novel formulation of Remune(R); 2002 [cited 2015 Oct 13]. Available from: http://www.prnewswire.com/news-releases/the-immune-response-corporation-granted-patent-in-south-africa-for-novel-formulation-of-remuner-77214627.html
   Google Scholar
• Immune Response BioPharma, Inc. About Immune Response BioPharma, Inc. FAQ; 2014 [cited 2015 Oct 13]. Available from: http://www.immuneresponsebiopharma.com/Pages/aboutus.aspx
   Google Scholar
• Levine AM, Groshen S, Allen J, et al. Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 Immunogen: long-term follow-up. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;11:351–364.
   PubMedGoogle Scholar
• Kinloch-de Loes S, Hoen B, Smith DE, et al. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis. 2005;192:607–617.
   PubMed Web of Science ®Google Scholar
• National Institute of Allergy and Infectious Diseases (NIAID). A phase III, randomized, double-blind, placebo-controlled evaluation of the effect of immunization with an HIV immunogen on the time to virologic relapse in individuals receiving potent, suppressive antiretroviral therapies; 2012 [cited 2015 Oct 13]. Available from: http://clinicaltrials.gov/ct2/show/record/NCT00005758
   Google Scholar
• Evaluate™. The Immune Response Corporation licenses Hybridon’s 2nd generation CpG DNA adjuvant, AMPLIVAX(TM), for use in development of a novel vaccine for the prevention and treatment of HIV; 2003 [cited 2015 Oct 13]. Available from: http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=133958
   Google Scholar
• Immune Response BioPharma, Inc. Remune + Amplivax IR103 HIV/AIDS phase III safety & efficacy study; 2015 [cited 2015 Oct 13]. Available from: www.clinicaltrials.gov/ct2/show/NCT02366026
   Google Scholar
• Churdboonchart V, Sakondhavat C, Kulpradist S, et al. A double-blind, adjuvant-controlled trial of human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) monotherapy in asymptomatic, HIV-1-infected Thai subjects with CD4-cell counts of >300. Clin Diagn Lab Immunol. 2000;7:728–733.
   PubMedGoogle Scholar
• Remune vaccine. Immune Response BioPharma, Inc. 2015 [cited 2015 Oct 13]. Available from: http://www.immuneresponsebiopharma.com/Pages/REMUNEVaccine.aspx
   Google Scholar
• Richieri SP, Bartholomew R, Aloia RC, et al. Characterization of highly purified, inactivated HIV-1 particles isolated by anion exchange chromatography. Vaccine. 1998;16:119–129.
   PubMed Web of Science ®Google Scholar
• Choi DJ, Dube S, Spicer TP, et al. HIV type 1 isolate Z321, the strain used to make a therapeutic HIV type 1 immunogen, is intersubtype recombinant. AIDS Res Hum Retroviruses. 1997;13:357–361.
   PubMed Web of Science ®Google Scholar
• Trauger RJ, Ferre F, Daigle AE, et al. Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells. J Infect Dis. 1994;169:1256–1264.
   PubMed Web of Science ®Google Scholar
• Moss RB, Ferre F, Levine A, et al. Viral load, CD4 percentage, and delayed-type hypersensitivity in subjects receiving the HIV-1 immunogen and antiviral drug therapy. J Clin Immunol. 1996;16:266–271.
   PubMed Web of Science ®Google Scholar
• Limsuwan A, Churdboonchart V, Moss RB, et al. Safety and immunogenicity of Remune in HIV-infected Thai subjects. Vaccine. 1998;16:142–149.
   PubMed Web of Science ®Google Scholar
• Churdboonchart V, Moss RB, Sirawaraporn W, et al. Effect of HIV-specific immune-based therapy in subjects infected with HIV-1 subtype E in Thailand. AIDS. 1998;12:1521–1527.
   PubMed Web of Science ®Google Scholar
• Patterson BK, Carlo DJ, Kaplan MH, et al. Cell-associated HIV-1 messenger RNA and DNA in T-helper cell and monocytes in asymptomatic HIV-1-infected subjects on HAART plus an inactivated HIV-1 immunogen. AIDS. 1999;13:1607–1611.
   PubMed Web of Science ®Google Scholar
• Hardy GA, Imami N, Nelson MR, et al. A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy. J Immune Based Ther Vaccines. 2007;5:6.
   PubMedGoogle Scholar
• Pido-Lopez J, Burton C, Hardy G, et al. Thymic output during initial highly active antiretroviral therapy (HAART) and during HAART supplementation with interleukin 2 and/or with HIV type 1 immunogen (Remune). AIDS Res Hum Retroviruses. 2003;19:103–109.
   PubMed Web of Science ®Google Scholar
• Moss RB, Brandt C, Giermakowska WK, et al. HIV-specific immunity during structured antiviral drug treatment interruption. Vaccine. 2003;21:1066–1071.
   PubMed Web of Science ®Google Scholar
• Huang KH, Boisvert MP, Chung F, et al. Longitudinal changes in HIV-specific IFN-gamma secretion in subjects who received Remune vaccination prior to treatment interruption. J Immune Based Ther Vaccines. 2006;4:7.
   PubMedGoogle Scholar
• Sei S, Sandelli SL, Theofan G, et al. Preliminary evaluation of human immunodeficiency virus type 1 (HIV-1) immunogen in children with HIV-1 infection. J Infect Dis. 1999;180:626–640.
   PubMed Web of Science ®Google Scholar
• Angel JB, Routy JP, Tremblay C, et al. A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune. AIDS. 2011;25:731–739.
   PubMed Web of Science ®Google Scholar
• Costiniuk CT, Kovacs C, Routy JP, et al. Short communication: human immunodeficiency virus rebound in blood and seminal plasma following discontinuation of antiretroviral therapy. AIDS Res Hum Retroviruses. 2013;29:266–269.
   PubMed Web of Science ®Google Scholar
• Sukeepaisarncharoen W, Churdboonchart V, Kulpradist S, et al. Long-term follow-up of HIV-1-infected Thai patients immunized with Remune monotherapy. HIV Clin Trials. 2001;2:391–398.
   PubMedGoogle Scholar
• Chantratita W, Sukeepaisarncharoen W, Chandeying V, et al. Delayed progression to AIDS in volunteers treated with long-term HIV-1 Immunogen (Remune) therapy in Thailand. HIV Med. 2004;5:317–325.
   PubMed Web of Science ®Google Scholar
• Robbins GK, Addo MM, Troung H, et al. Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization. AIDS. 2003;17:1121–1126.
   PubMed Web of Science ®Google Scholar
• Fernandez-Cruz E, Moreno S, Navarro J, et al. Therapeutic immunization with an inactivated HIV-1 Immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects. Vaccine. 2004;22:2966–2973.
   PubMed Web of Science ®Google Scholar
• Valor L, Navarro J, Carbone J, et al. Immunization with an HIV-1 immunogen induces CD4+ and CD8+ HIV-1-specific polyfunctional responses in patients with chronic HIV-1 infection receiving antiretroviral therapy. Vaccine. 2008;26:2738–2745.
   PubMed Web of Science ®Google Scholar
• Moss RB, Ferre F, Trauger R, et al. Inactivated HIV-1 Immunogen: impact on markers of disease progression. J Acquir Immune Defic Syndr. 1994;7(Suppl 1):S21–S27.
   Google Scholar
• Trauger RJ, Daigle AE, Giermakowska W, et al. Safety and immunogenicity of a gp120-depleted, inactivated HIV-1 immunogen: results of a double-blind, adjuvant controlled trial. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10(Suppl 2):S74–S82.
   Google Scholar
• Kahn JO, Cherng DW, Mayer K, et al. Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 106/L CD4 cell counts: a randomized controlled trial. JAMA. 2000;284:2193–2197.
   PubMed Web of Science ®Google Scholar
• The Immune Response Corporation. A multicenter, double-blind, phase III, adjuvant-controlled study of the effect of 10 units of HIV-1 Immunogen (Remune) compared to Incomplete Freund’s Adjuvant (IFA) alone every 12 weeks on AIDS-free survival in subjects with HIV infection and CD4 T-lymphocytes between 300 and 549 cells/microL regardless of concomitant HIV therapies; 2005 [cited 2015 Oct 13]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00002359
   Google Scholar
• Turner JL, Kostman JR, Aquino A, et al. The effects of an HIV-1 immunogen (Remune) on viral load, CD4 cell counts and HIV-specific immunity in a double-blind, randomized, adjuvant-controlled subset study in HIV infected subjects regardless of concomitant antiviral drugs. HIV Med. 2001;2:68–77.
   PubMedGoogle Scholar
• Kahn JO, Lagakos S. Letters. Outcomes of a trial of HIV-1 Immunogen in patients with HIV infection (in reply). JAMA. 2001;285:2191–2195.
   Google Scholar
• Glidden D, Kim S, Lagakos S. Effectiveness of Remune. Clin Diagn Lab Immunol. 2001;8:468–469.
   PubMedGoogle Scholar
• Lurie P, Wolfe SM. Letters. Outcomes of a trial of HIV-1 immunogen in patients with HIV infection. JAMA. 2001;285:2193–2195.
   PubMed Web of Science ®Google Scholar
• Editorial. Collaborative conflicts. Nat Immunol. 2000;1:449.
   PubMed Web of Science ®Google Scholar
• Morton CC. Clinical trials. Company, researchers battle over data access. Science. 2000;290:1063.
   PubMed Web of Science ®Google Scholar
• Immune Response BioPharma, Inc files BLA with the FDA for Remune HIV/AIDS vaccine marketing approval [Press Release]. Immune Response BioPharma. 2014 [cited 2016 Jan 19]. Available from: http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=550140
   Google Scholar
• Immune Response BioPharma, Inc. announces Remune FDA BLA assignment PDUFA goal December 22nd 2015 [Press Release] [Internet]. Immune Response BioPharma. 2015 [cited 2016 Jun 1]. Available from: http://www.biospace.com/news_story.aspx?StoryID=364821
   Google Scholar
• Immune Response BioPharma, Inc. Provides Remune BLA FDA filing update [Press Release]. Immune Response BioPharma [Internet]. 2015 [cited 2016 Jun 1]. Available from: http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=567945
   Google Scholar
• Immune Response BioPharma, Inc. announces the FDA has accepted Remune HIV/AIDS vaccine BLA for review [Press Release] [Internet]. Immune Response BioPharma. 2015 [cited 2016 Jan 19]. Available from: https://www.evaluategroup.com/Universal/View.aspx?type=Story&id=567944
   Google Scholar
• U.S. Food and Drug Administration. Remune orphan drug designation [Internet]. 2014 [cited 2016 Jun 1]. Available from: http://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=420113
   Google Scholar
• Immune Response BioPharma, Inc. Remune HIV/AIDS vaccine Phase II pediatric safety & efficacy clinical study; 2015 [cited 2015 Oct 13]. Available from: http://clinicaltrials.gov/ct2/show/NCT02291809
   Google Scholar
• Anderson JL, Fromentin R, Corbelli GM, et al. Progress towards an HIV cure: update from the 2014 International AIDS Society Symposium. AIDS Res Hum Retroviruses. 2015;31:36–44.
   PubMed Web of Science ®Google Scholar
• Thornhill J, Fidler S, Frater J. Advancing the HIV cure agenda: the next 5 years. Curr Opin Infect Dis. 2015;28:1–9.
   PubMed Web of Science ®Google Scholar
• Western University. HIV/AIDS vaccine developed at the University of Western Ontario proceeding to human clinical trials [Internet]. 2011 [cited 2015 Oct 13]. Available from: www.schulich.uwo.ca/schulichhome/articles/2011/12/20/hiv-aids-vaccine-developed-at-the-university-of-western-ontario-proceeding-to-human-clinical-trials
   Google Scholar
• Immune Response BioPharma, Inc. receives FDA Complete Response Letter for Remune HIV vaccine [Press Release] [Internet]. Immune Response BioPharma. 2015 [cited 2016 May 31]. Available from: http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=623610
   Google Scholar